A
ADCT
ADC Therapeutics SA
$1.45
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of ADC Therapeutics SA in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.73
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.22
Nov 10
Posts
No posts about ADCT yet.
About ADC Therapeutics SA
ADC Therapeutics is a Swiss biotechnology company that develops cancer drugs called antibody drug conjugates. These work like guided missiles: an antibody finds cancer cells and delivers a toxic payload straight to them. The company sells Zynlonta, approved for a type of lymphoma (a blood cancer), and earns money from those sales plus partnership and licensing deals.